POINT - Platelet-Oriented Inhibition in New TIA and Minor Ischaemic Stroke Trial
Registered with ClinicalTrials.gov: NCT00991029
NIH Project Number: 5U01NS062835-05
POINT is a randomized, double-blind, multicenter clinical trial to determine whether clopidogrel 75mg/day (after a loading dose of 600mg) is effective in improving survival free from major ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours time last known free of new ischemic symptoms of TIA or minor ischemic stroke in subjects receiving aspirin 50-325mg/day.
The POINT Trial is currently recruiting sites. If your site is interested in participating in the trial, please contact the POINT CRC at 1-800-305-7811.
POINT patient recruitment initiated in May 2010.
For more background and trial information, please visit the POINT website at www.pointtrial.org.